- Home
- DIN vs URGN Comparison
DIN vs URGN Comparison
Compare DIN & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIN
- URGN
- Stock Information
- Founded
- DIN 1958
- URGN 2004
- Country
- DIN United States
- URGN United States
- Employees
- DIN N/A
- URGN N/A
- Industry
- DIN Restaurants
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- DIN Consumer Discretionary
- URGN Health Care
- Exchange
- DIN Nasdaq
- URGN Nasdaq
- Market Cap
- DIN 468.5M
- URGN 465.9M
- IPO Year
- DIN 1991
- URGN 2017
- Fundamental
- Price
- DIN $23.32
- URGN $11.06
- Analyst Decision
- DIN Hold
- URGN Strong Buy
- Analyst Count
- DIN 8
- URGN 6
- Target Price
- DIN $29.50
- URGN $40.75
- AVG Volume (30 Days)
- DIN 691.0K
- URGN 418.3K
- Earning Date
- DIN 03-05-2025
- URGN 03-10-2025
- Dividend Yield
- DIN 8.77%
- URGN N/A
- EPS Growth
- DIN N/A
- URGN N/A
- EPS
- DIN 4.22
- URGN N/A
- Revenue
- DIN $812,306,000.00
- URGN $90,398,000.00
- Revenue This Year
- DIN $1.02
- URGN $43.60
- Revenue Next Year
- DIN $1.15
- URGN $103.77
- P/E Ratio
- DIN $5.51
- URGN N/A
- Revenue Growth
- DIN N/A
- URGN 9.29
- 52 Week Low
- DIN $22.36
- URGN $9.03
- 52 Week High
- DIN $47.19
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- DIN 38.26
- URGN 50.86
- Support Level
- DIN $23.84
- URGN $11.12
- Resistance Level
- DIN $25.10
- URGN $11.91
- Average True Range (ATR)
- DIN 1.06
- URGN 0.57
- MACD
- DIN -0.06
- URGN -0.02
- Stochastic Oscillator
- DIN 10.00
- URGN 26.40
About DIN Dine Brands Global Inc.
Dine Brands Global Inc owns and franchises thousands of restaurants under the Applebee's and International House of Pancakes names. Almost all company restaurants are located in the United States and franchised. Royalty revenue, which the company gets from franchisees based on franchisees' sales, accounts for roughly three-quarters of total company revenue. The company also earns revenue by leasing restaurant sites to franchisees. The company has four reportable segments Franchise operations, (an aggregation of Applebee's and IHOP franchise operations), Rental operations, Financing operations, and Company-operated restaurant operations. The majority of revenue is derived from the Franchise operations segment.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.